Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:BDTX NYSE:CPHI NASDAQ:FTLF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.06-5.0%$2.80$2.32▼$5.46$104.11M0.59289,057 shs192,452 shsBDTXBlack Diamond Therapeutics$1.91+1.6%$2.21$1.60▼$4.94$109.45M3.252.13 million shs1.05 million shsCPHIChina Pharma$0.57-11.0%$0.73$0.38▼$2.03$23.10M1.14402,542 shs30.71 million shsFTLFFitLife Brands$11.21+1.0%$10.51$8.67▼$20.98$105.27M0.0142,190 shs14,212 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences0.00%-6.42%+22.40%+13.75%-2.86%BDTXBlack Diamond Therapeutics0.00%-4.98%+4.95%-25.39%-27.65%CPHIChina Pharma0.00%-20.61%-25.67%-7.47%-66.47%FTLFFitLife Brands0.00%-2.52%-3.20%+16.53%-16.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.06-5.0%$2.80$2.32▼$5.46$104.11M0.59289,057 shs192,452 shsBDTXBlack Diamond Therapeutics$1.91+1.6%$2.21$1.60▼$4.94$109.45M3.252.13 million shs1.05 million shsCPHIChina Pharma$0.57-11.0%$0.73$0.38▼$2.03$23.10M1.14402,542 shs30.71 million shsFTLFFitLife Brands$11.21+1.0%$10.51$8.67▼$20.98$105.27M0.0142,190 shs14,212 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences0.00%-6.42%+22.40%+13.75%-2.86%BDTXBlack Diamond Therapeutics0.00%-4.98%+4.95%-25.39%-27.65%CPHIChina Pharma0.00%-20.61%-25.67%-7.47%-66.47%FTLFFitLife Brands0.00%-2.52%-3.20%+16.53%-16.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 2.40Hold$8.50177.78% UpsideBDTXBlack Diamond Therapeutics 2.73Moderate Buy$9.83414.83% UpsideCPHIChina Pharma 0.00N/AN/AN/AFTLFFitLife Brands 2.25Hold$21.5091.79% UpsideCurrent Analyst Ratings BreakdownLatest CPHI, BDTX, ANIX, and FTLF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.006/17/2026ANIXAnixa Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/12/2026ANIXAnixa Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/12/2026ANIXAnixa Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/4/2026FTLFFitLife Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)5/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/29/2026BDTXBlack Diamond Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.00(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K495.72N/AN/A$0.42 per share7.29BDTXBlack Diamond Therapeutics$70M1.56$0.53 per share3.62$1.97 per share0.97CPHIChina Pharma$3.99M5.79N/AN/A$0.70 per share0.81FTLFFitLife Brands$81.46M1.29$1.17 per share9.61$4.65 per share2.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$10.93M-$0.31N/AN/AN/AN/A-71.12%-62.88%9/10/2026 (Estimated)BDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)CPHIChina Pharma-$3.08M-$0.55N/AN/AN/A-85.56%-63.93%-31.42%N/AFTLFFitLife Brands$6.33M$0.6018.569.75N/A6.64%18.31%8.21%N/ALatest CPHI, BDTX, ANIX, and FTLF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026BDTXBlack Diamond Therapeutics-$0.18N/AN/AN/AN/AN/A6/10/2026Q2 2026ANIXAnixa Biosciences-$0.10-$0.07+$0.03-$0.07N/AN/A5/14/2026Q1 2026FTLFFitLife Brands$0.14$0.17+$0.03$0.17N/A$25.33 million5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/ABDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A9.799.79BDTXBlack Diamond TherapeuticsN/A8.468.46CPHIChina Pharma0.220.790.26FTLFFitLife Brands0.781.520.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%BDTXBlack Diamond Therapeutics95.47%CPHIChina PharmaN/AFTLFFitLife Brands2.32%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences26.40%BDTXBlack Diamond Therapeutics9.29%CPHIChina Pharma6.40%FTLFFitLife Brands61.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences534.02 million25.04 millionOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableCPHIChina Pharma25040.52 million15.92 millionNot OptionableFTLFFitLife Brands209.39 million3.60 millionNot OptionableCPHI, BDTX, ANIX, and FTLF HeadlinesRecent News About These CompaniesFitLife Brands (FTLF) Stock Fair Value Moves Lower After Analysts Cut Growth ViewsJune 27, 2026 | finance.yahoo.comFitLife Brands: The Acquisition Of Irwin Naturals Is Already Paying OffJune 25, 2026 | seekingalpha.comJoey Chestnut Teams Up with Dr. Tobias for New Campaign: “Cleanse Like a Winner”June 9, 2026 | globenewswire.comChallenges in Online Sales Hurt FitLife Brands (FTLF) in Q1June 4, 2026 | insidermonkey.comFitLife (FTLF) Q4 2025 Earnings Call TranscriptMay 29, 2026 | finance.yahoo.comInvestors Can Find Comfort In FitLife Brands' (NASDAQ:FTLF) Earnings QualityMay 29, 2026 | finance.yahoo.comFitLife Brands, Inc. (NASDAQ:FTLF) Q1 2026 Earnings Call TranscriptMay 16, 2026 | insidermonkey.comFitLife Brands Inc (FTLF) Q1 2026 Earnings Call Highlights: Revenue Surge Amidst Acquisition GainsMay 15, 2026 | finance.yahoo.comFitLife Brands, Inc. (FTLF) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comFitLife Brands Inc. (FTLF) Surpasses Q1 Earnings EstimatesMay 14, 2026 | zacks.comFitLife Brands Announces First Quarter 2026 ResultsMay 14, 2026 | globenewswire.comFitLife Brands Announces First Quarter Earnings CallMay 5, 2026 | globenewswire.comFitLife Will Need To See Real Progress To Remain In Our PortfolioApril 29, 2026 | seekingalpha.comBear of the Day: FitLife Brands (FTLF)April 21, 2026 | zacks.comRoth Capital Highlights Discontinued CBD Products Weighing on FitLife Brands, Inc. (FTLF)April 17, 2026 | finance.yahoo.comFitLife Brands (FTLF) Gets a Buy from Roth MKMApril 16, 2026 | theglobeandmail.com5 Best Beaten Down Stocks to Invest in According to AnalystsApril 16, 2026 | insidermonkey.comFitLife Brands (NASDAQ:FTLF) Director Buys $29,280.00 in StockApril 15, 2026 | insidertrades.comFitLife Brands' Recent Selloff Was Justified (Rating Downgrade)April 10, 2026 | seekingalpha.comFitLife Brands (FTLF) price target decreased by 23.91% to 17.85April 9, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPHI, BDTX, ANIX, and FTLF Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.06 -0.16 (-4.97%) As of 07/10/2026 04:00 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Black Diamond Therapeutics NASDAQ:BDTX$1.91 +0.03 (+1.60%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$1.90 0.00 (-0.26%) As of 07/10/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.China Pharma NYSE:CPHI$0.57 -0.07 (-10.97%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$0.63 +0.06 (+10.18%) As of 07/10/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.FitLife Brands NASDAQ:FTLF$11.21 +0.11 (+0.99%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$11.14 -0.08 (-0.67%) As of 07/10/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Why "Big Short" Investor Michael Burry Sees Upside in Beaten-Down Sportbook Stocks Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
